Neoleukin Therapeutics, Inc. (AQXP) [Rocket]

Overview

Neoleukin Therapeutics, Inc. (AQXP)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	SC 13D/A	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/10/2023	4	BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.
10/05/2023	425	Form 425 - Prospectuses and communications, business combinations:
09/28/2023	S-4/A	Form S-4/A - Registration of securities, business combinations: [Amend]
08/17/2023	SC 13D/A	BAKER BROS. ADVISORS LP reports a 20% stake in Neoleukin Therapeutics, Inc.
08/17/2023	4	BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.
08/14/2023	4	Smith Sean Michael (Interim CFO, Prin Acct Off) has filed a Form 4 on Neoleukin Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	0.0	0.0	75.3	94.2	25.0	36.3	0.6	0.1
Revenue growth		-100.0%	-20.1%	276.8%	-31.1%	5944.5%	500.0%
Cost of goods sold	0.0	0.0	0.0	0.0	57.6	51.1	0.6	0.0
Gross profit	0.0	0.0	75.3	94.2	-32.6	-14.9	0.0	0.1
Gross margin			100.0%	100.0%	-130.5%	-41.0%	0.0%	100.0%
Research and development	41.1	39.2	24.3	4.4			28.4	15.8
General and administrative	18.0	21.5	17.2	18.8	15.8	14.9	9.3	5.5
EBITA	-59.0	-60.5	26.1	71.0	-32.6	-51.1	-37.6	-21.3
EBITA margin			34.7%	75.3%	-130.5%	-141.0%	-6274.2%	-21340.0%
Amortization of intangibles	0.1	0.2	0.2
EBIT	-59.1	-60.7	25.9	71.0	-32.6	-51.1	-37.6	-21.3
EBIT margin			34.4%	75.3%	-130.5%	-141.0%	-6274.2%	-21340.0%
Pre-tax income	-57.6	-60.7	-33.3	-69.4	-31.6	-50.2	-37.0	-21.9
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-57.6	-60.7	-33.3	-69.4	-31.6	-50.2	-37.0	-21.9
Net margin			-44.2%	-73.7%	-126.3%	-138.4%	-6167.0%	-21860.0%

Diluted EPS	($1.04)	($1.10)	($0.64)	($2.57)	($1.34)	($2.14)	($1.96)	($1.73)
Shares outstanding (diluted)	55.2	55.0	51.8	27.0	23.5	23.5	18.9	12.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.